Halozyme Therapeutics, Inc.
HALO
$62.54
-$0.41-0.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.44% | 21.35% | 12.88% | 22.41% | 25.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.44% | 21.35% | 12.88% | 22.41% | 25.62% |
| Cost of Revenue | -11.26% | -3.92% | 0.88% | 13.72% | 30.50% |
| Gross Profit | 38.59% | 33.94% | 18.67% | 26.66% | 23.41% |
| SG&A Expenses | 3.45% | 17.48% | 13.51% | 1.25% | 22.66% |
| Depreciation & Amortization | -0.31% | 22.37% | 5.51% | 16.76% | 65.18% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.18% | 5.63% | 5.17% | 10.00% | 31.97% |
| Operating Income | 62.16% | 42.20% | 23.37% | 42.70% | 17.50% |
| Income Before Tax | 59.94% | 51.00% | 43.75% | 72.93% | 39.94% |
| Income Tax Expenses | 69.39% | 36.84% | 41.34% | 62.53% | 42.63% |
| Earnings from Continuing Operations | 57.71% | 54.57% | 44.32% | 75.52% | 39.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.71% | 54.57% | 44.32% | 75.52% | 39.31% |
| EBIT | 62.16% | 42.20% | 23.37% | 42.70% | 17.50% |
| EBITDA | 50.41% | 38.69% | 20.03% | 37.71% | 24.06% |
| EPS Basic | 63.48% | 61.49% | 50.70% | 83.74% | 44.87% |
| Normalized Basic EPS | 71.40% | 52.24% | 34.43% | 57.82% | 26.97% |
| EPS Diluted | 62.32% | 60.60% | 50.85% | 84.62% | 45.50% |
| Normalized Diluted EPS | 70.67% | 52.12% | 34.94% | 59.13% | 28.08% |
| Average Basic Shares Outstanding | -3.88% | -4.50% | -4.36% | -4.60% | -3.59% |
| Average Diluted Shares Outstanding | -3.60% | -4.57% | -4.77% | -5.47% | -4.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
